What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial
Aim of the study was to examine the course of schizophrenia patients within 2 years after discharge. Within a multicenter study of the German Competence Network on Schizophrenia, patients suffering from a schizophrenia spectrum disorder were examined regarding their psychopathological improvement, tolerability, and the treatment regime applied during hospitalization and a 2-year follow-up period. Response, remission, the level of everyday functioning, and relapse were furthermore evaluated during the follow-up period using established definitions for these outcome domains. The psychopharmacological treatment was specifically evaluated in terms of a potential association with relapse. 149 patients were available for analysis, with 65% of the patients being in response, 52% in symptomatic remission, and 64% having a satisfiable everyday functioning 2 years after their discharge from hospital. Despite these favorable outcome rates, 63% of the patients suffered from a relapse within the 2-year follow-up period with 86% of these patients being rehospitalized. Discharge non-responder and non-remitter were twice as likely to relapse during follow-up. A significant decrease of side-effects was observed with negligible rates of extrapyramidal side-effects, sedation, and weight gain during follow-up. Patients receiving treatment with atypical antipsychotics were found to have the lowest risk to relapse (p < 0.0001). The results highlight the natural and unsteady course of schizophrenia in most patients underlining the need to develop more specific treatment strategies ensuring ongoing stability and preventing relapse.
KeywordsSchizophrenia Response Remission Functioning Relapse 2-year follow-up
The study was performed within the framework of the German Research Network on Schizophrenia, which is funded by the German Federal Ministry for Education and Research BMBF (Grant 01 GI 0233).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest within the context of this study.
- 3.Herceg M, Jukic V, Vidovic D, Erdeljic V, Celic I, Kozumplik O, Bagaric D, Silobrcic RM (2008) Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. Croat Med J 49:215–223CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Moller HJ (2007) Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257:47–53CrossRefPubMedGoogle Scholar
- 13.American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington DCGoogle Scholar
- 24.Stauffer V, Case M, Kollack-Walker S, Scher-Svanum H, Ball T, Kapur S, Kinon BJ (2011) Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 130:11–19CrossRefPubMedGoogle Scholar
- 28.Moller HJ, Jager M, Riedel M, Obermeier M, Strauss A, Bottlender R (2010) The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur Arch Psychiatry Clin Neurosci 260:367–384CrossRefPubMedGoogle Scholar
- 33.Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Maier W, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Moller HJ, Riedel M (2009) Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res 113:210–217CrossRefPubMedGoogle Scholar
- 36.Schennach-Wolff R, Moller HJ, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Riedel M (2010) A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Pharmacopsychiatry 43:245–251CrossRefPubMedGoogle Scholar
- 44.Dossenbach M, Rango-Davila C, Silva IH, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S (2005) Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66:1021–1030CrossRefPubMedGoogle Scholar
- 45.Alptekin K, Aydin H, Gucer KM, Dilbaz N, Goka E, Esendemir C, Oguz H, Arabul G, Aslaner F, Ayer A, Celiker AR, Cirit H, Pinar Z, Unal A (2010) Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study. Int Clin Psychopharmacol 25:342–348CrossRefPubMedGoogle Scholar